Literature DB >> 7214270

Urinary tract infections due to Staphylococcus saprophyticus biotype 3.

J D Anderson, A M Clarke, M E Anderson, J L Isaac-Renton, M G McLoughlin.   

Abstract

Staphylococcus saprophyticus biotype 3 (Micrococcus subgroup 3 or M3) has usually been shown to be the second commonset cause of urinary tract infections in European women who are not in hospital. It generally causes pyuria and symptoms as severe as those caused by Escherichia coli. Unlike S. epidermidis it is seldom found as a contaminant in midstream urine specimens, and almost exclusively infects women in their reproductive years. However, S. saprophyticus is seldom differentiated from S. epidermidis in Canadian clinical laboratories. Urinary isolates of S. saprophyticus were presumptively differentiated from other coagulase-negative Micrococcaceae by their resistance to novobiocin as demonstrated by a simple disc susceptibility test that misidentified the infecting organism in only 3.4% of specimens. These novobiocin-resistant, coagulase-negative organisms caused similar proportions of the urinary tract infections in young women in York, England and Vancouver -- 6.6% and 6.9% respectively. In York these organisms were associated with significantly greater pyuria than novobiocin-sensitive organisms or bile-tolerant streptococci but not S. aureus or Enterobacteriaceae. In both communities novobiocin-sensitive, coagulase-negative Micrococcaceae were appreciably more resistant to penicillin than novobiocin-resistant organisms. Thus, differentiating S. saprophyticus from novobiocin-sensitive, coagulase-negative organisms provides information that is clinically useful, particularly for primary care practitioners working in the community or in outpatient clinics.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7214270      PMCID: PMC1705246     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  21 in total

1.  Simplified scheme for routine identification of human Staphylococcus species.

Authors:  W E Kloos; K H Schleifer
Journal:  J Clin Microbiol       Date:  1975-01       Impact factor: 5.948

2.  Importance of coagulase-negative staphylococci as pathogens in the urinary tract.

Authors:  R Maskell
Journal:  Lancet       Date:  1974-06-08       Impact factor: 79.321

3.  [Editorial: News in methods of family planning].

Authors:  M Lancet
Journal:  Harefuah       Date:  1974-06-02

4.  Classification of Staphylococcus albus strains isolated from the urinary tract.

Authors:  R G Mitchell
Journal:  J Clin Pathol       Date:  1968-01       Impact factor: 3.411

5.  Letter: Urinary infections in general practice.

Authors:  J Crump; L Pead; R Maskell
Journal:  Lancet       Date:  1976-05-29       Impact factor: 79.321

6.  Characterization of Micrococcaceae from the urinary tract.

Authors:  A Digranes; P Oeding
Journal:  Acta Pathol Microbiol Scand B       Date:  1975-08

7.  Significance of urinary isolates of coagulase-negative Micrococcaceae.

Authors:  D N Williams; M E Lund; D J Blazevic
Journal:  J Clin Microbiol       Date:  1976-06       Impact factor: 5.948

8.  Coagulase-negative staphylococci and micrococci in urinary tract infections.

Authors:  P D Meers; W Whyte; G Sandys
Journal:  J Clin Pathol       Date:  1975-04       Impact factor: 3.411

9.  Micrococcal urinary-tract infections in young women.

Authors:  M Sellin; D I Cooke; W A Gillespie; D G Sylvester; J D Anderson
Journal:  Lancet       Date:  1975-09-27       Impact factor: 79.321

10.  Urinary infection caused by Micrococcus subgroup 3.

Authors:  H Kerr
Journal:  J Clin Pathol       Date:  1973-12       Impact factor: 3.411

View more
  14 in total

1.  Rapid, automated identification of novobiocin-resistant, coagulase-negative staphylococci.

Authors:  C M Mendes; L F Siqueira; W Francisco
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

2.  Five-hour novobiocin test for differentiation of coagulase-negative staphylococci.

Authors:  B J Harrington; J M Gaydos
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

3.  Rapid determination of novobiocin resistance of coagulase-negative staphylococci with the MS-2 system.

Authors:  R J Almeida; J H Jorgensen
Journal:  J Clin Microbiol       Date:  1983-03       Impact factor: 5.948

4.  Antimicrobial susceptibilities of coagulase-negative staphylococci isolated from urinary infections.

Authors:  A M Bourgault; L Gauvreau
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

5.  Antimicrobial susceptibility of Staphylococcus saprophyticus and urethral staphylococci.

Authors:  T J Marrie; C Kwan
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

6.  Speciation of coagulase-negative staphylococci in the clinical laboratory.

Authors:  P D Ellner; B Myrick
Journal:  Eur J Clin Microbiol       Date:  1982-04       Impact factor: 3.267

7.  Use of Mueller-Hinton agar to determine novobiocin susceptibility of coagulase-negative staphylococci.

Authors:  R J Almeida; J H Jorgensen
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

8.  Susceptibility of clinical isolates of Staphylococcus saprophyticus to fifteen commonly used antimicrobial agents.

Authors:  L E Nicolle; G K Harding
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

9.  Use of trehalose-mannitol-phosphatase agar to differentiate Staphylococcus epidermidis and Staphylococcus saprophyticus from other coagulase-negative staphylococci.

Authors:  D L Stevens; C Jones
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

10.  Identification, clinical distribution, and susceptibility to methicillin and 18 additional antibiotics of clinical Staphylococcus isolates: nationwide investigation in Italy.

Authors:  P E Varaldo; P Cipriani; A Focá; C Geraci; A Giordano; M A Madeddu; A Orsi; R Pompei; M Prenna; A Repetto
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.